The prospective, observational XANTUS study demonstrated low rates of stroke and major bleeding in real-world rivaroxaban-treated patients with non-valvular ...
Patients with Atrial Fibrillation in Asia) and XANTUS-EL (Xarelto® for ... results from previous phase III trials, including ROCKET AF (Rivaroxaban ...
01.12.2018 · XANTUS-EL (Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Eastern Europe, the Middle East and Africa [EEMEA] and Latin America) was the first real-world, prospective, observational study assessing rivaroxaban use in a broad patient population with NVAF in 17 countries across EEMEA and Latin America.
XANTUS is the first international, prospective, observational study to describe the use of rivaroxaban in a broad NVAF patient population. Rates of stroke and major bleeding were low in patients...
Study design. A large, prospective, observational, single-arm, non-interventional study to evaluate the safety and efficacy of Xarelto® in the real world1 ...
Conclusion: XANTUS is the first international, prospective, observational study to describe the use of rivaroxaban in a broad NVAF patient population. Rates of stroke and major bleeding were low in patients receiving rivaroxaban in routine clinical practice. Trial registration number: Clinicaltrials.gov: NCT01606995.
Aims: Based on Phase III data, non-vitamin K antagonist oral anticoagulants are recommended for stroke prevention in patients with atrial fibrillation.
Sep 01, 2015 · Font Size A A A Atrial fibrillation (AFib) patients treated with rivaroxaban for stroke prevention have low rates of bleeding and stroke, according to data from the XANTUS study presented Sept. 1 during ESC Congress 2015 in London and simultaneously published in European Heart Journal.
Conclusion: XANTUS is the first international, prospective, observational study to describe the use of rivaroxaban in a broad NVAF patient population. Rates of stroke and major bleeding were low in patients receiving rivaroxaban in routine clinical practice. Trial registration number: Clinicaltrials.gov: NCT01606995.
17.07.2014 · XANTUS (Xarelto (®) for Prevention of Stroke in Patients with Atrial Fibrillation) is a prospective, international, observational, postauthorization, noninterventional study designed to collect safety and efficacy data on the use of rivaroxaban for stroke prevention in AF in routine clinical practice.
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation (XANTUS) ... Brief Summary: This is an international observational study in patients with ...
07.04.2016 · XANTUS is the first international, prospective, observational study to describe the use of rivaroxaban in a broad NVAF patient population. Rates of stroke and major bleeding were low in patients receiving rivaroxaban in routine clinical practice. Trial registration number
Jul 17, 2014 · XANTUS (Xarelto (®) for Prevention of Stroke in Patients with Atrial Fibrillation) is a prospective, international, observational, postauthorization, noninterventional study designed to collect safety and efficacy data on the use of rivaroxaban for stroke prevention in AF in routine clinical practice.